Kazia Therapeutics LTD KZIA
We take great care to ensure that the data presented and summarized in this overview for KAZIA THERAPEUTICS LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KZIA
View all-
Morgan Stanley New York, NY201KShares$68,3670.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA41.5KShares$14,1020.0% of portfolio
-
Virtu Financial LLC New York, NY39.3KShares$13,3540.0% of portfolio
-
Ubs Group Ag23.3KShares$7,9340.0% of portfolio
-
Rhumbline Advisers Boston, MA17.6KShares$5,9890.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.57KShares$1,5520.0% of portfolio
-
Wells Fargo & Company San Francisco, CA500Shares$1700.0% of portfolio
-
Cordasco Financial Network125Shares$420.0% of portfolio
-
Allworth Financial LP87Shares$290.0% of portfolio
-
Advisor Net Financial, Inc5Shares$10.0% of portfolio
Latest Institutional Activity in KZIA
Top Purchases
Top Sells
About KZIA
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Insider Transactions at KZIA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|